Novartis to Acquire Breast Cancer Drug in Up to $3 Billion Deal

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion in a push to bolster its oncology pipeline.

By Karthikeyan Sundaram · Bloomberg

Novartis AG agreed to buy an experimental breast cancer drug from Synnovation Therapeutics for as much as $3 billion in a push to bolster its oncology pipeline.